Literature DB >> 16607651

The clinical impact of histopathologic response assessment by residual tumor cell quantification in esophageal squamous cell carcinomas.

Björn L D M Brücher1, Karen Becker, Florian Lordick, Ulrich Fink, Mario Sarbia, Hubert Stein, Raymonde Busch, Frank Zimmermann, Michael Molls, Heinz Höfler, Jörg R Siewert.   

Abstract

BACKGROUND: The objectives of this study were to investigate histomorphologic features as a response classification after neoadjuvant radiochemotherapy (RTx/CTx) and to correlate the results with clinical outcome parameters (e.g., postoperative morbidity and mortality, recurrence, and survival) in patients with locally advanced esophageal squamous cell carcinoma (ESCC).
METHODS: Three hundred eleven patients with histologically proven, locally advanced, intrathoracic ESCC (clinical T3 or T4, N0-N+, M0) located at or above the level of the tracheal bifurcation underwent preoperative, combined, simultaneous RTx/CTx followed by esophagectomy. Response to RTx/CTx was classified by the quantification of residual tumor cells. A histopathologic response was defined as <10% residual tumor cells found within the specimen compared with a histopathologic nonresponse, which was characterized by >10% residual tumor cells.
RESULTS: A histopathologic response was correlated significantly with complete tumor resection status (R0 resection) (P .0001), histopathologic tumor (ypT) category (P <.0001), lymph node involvement (P <.0001), lymphatic vessel invasion (P <.001), and survival (P <.0001). A multivariate Cox regression analysis revealed that histopathologic response classification according to the percentage of residual tumor cells was an independent prognostic factor (P <.0001). Nonresponders had greater postoperative pulmonary morbidity (P = .01), a greater 30-day mortality rate (P = .02), and a dismal survival rate compared to histopathologic responders (P <.0001).
CONCLUSIONS: Histopathologic response evaluation based on the quantification of residual tumor cells provided meaningful information for the assessment of outcomes among patients with ESCC who have underwent neoadjuvant RTx/CTx. The current results indicated that histopathologic responders may represent a subgroup of patients who benefit from neoadjuvant therapy followed by surgery. Copyright 2006 American Cancer Society

Entities:  

Mesh:

Year:  2006        PMID: 16607651     DOI: 10.1002/cncr.21850

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  41 in total

1.  [Response prediction--early response evaluation. Consequences for surgical oncology].

Authors:  J R Siewert; F Lordick
Journal:  Chirurg       Date:  2006-12       Impact factor: 0.955

Review 2.  [Squamous cell carcinoma of the esophagus].

Authors:  K Ott; L Sisic; M Büchler
Journal:  Chirurg       Date:  2011-11       Impact factor: 0.955

3.  Expression and prognostic value of ZNRD1 in esophageal squamous cell carcinoma.

Authors:  Yunping Zhao; Liu Hong; Ruwen Wang; Daiming Fan
Journal:  Dig Dis Sci       Date:  2008-07-02       Impact factor: 3.199

4.  Neoadjuvant concurrent chemoradiotherapy with capecitabine and oxaliplatin in patients with locally advanced esophegeal cancer.

Authors:  Hanan Ahmed Wahba; Hend Ahmed El-Hadaad; Ehab Atef Abd-Ellatif
Journal:  Med Oncol       Date:  2011-06-26       Impact factor: 3.064

Review 5.  Tumor regression grading of gastrointestinal cancers after neoadjuvant therapy.

Authors:  Rupert Langer; Karen Becker
Journal:  Virchows Arch       Date:  2017-09-16       Impact factor: 4.064

6.  Outcome, complications, and mortality of an intrathoracic anastomosis in esophageal cancer in patients without a preoperative selection with a risk score.

Authors:  Ingo Alldinger; Leila Sisic; Marcel Hochreiter; Wilko Weichert; Susanne Blank; Maria Burian; Lars Grenacher; Tom Bruckner; Jens Werner; Markus W Büchler; Katja Ott
Journal:  Langenbecks Arch Surg       Date:  2014-11-20       Impact factor: 3.445

Review 7.  [Pretherapeutic misclassification of esophageal cancer and adenocarcinoma of the esophagogastric junction : Possibilities and clinical consequences].

Authors:  I Gockel; F Lordick; O Lyros; N Kreuser; A H Hölscher; C Wittekind
Journal:  Chirurg       Date:  2020-01       Impact factor: 0.955

8.  Preoperative therapy of esophagogastric cancer: the problem of nonresponding patients.

Authors:  S Blank; A Stange; L Sisic; W Roth; L Grenacher; F Sterzing; M Burian; D Jäger; M Büchler; K Ott
Journal:  Langenbecks Arch Surg       Date:  2012-12-07       Impact factor: 3.445

9.  The predictive value of genes of the TGF-beta1 pathway in multimodally treated squamous cell carcinoma of the esophagus.

Authors:  Franziska Pühringer-Oppermann; Mario Sarbia; Nicola Ott; Björn L D M Brücher
Journal:  Int J Colorectal Dis       Date:  2009-12-15       Impact factor: 2.571

10.  Histological regression of squamous esophageal carcinoma assessed by percentage of residual viable cells after neoadjuvant chemoradiation is an important prognostic factor.

Authors:  Daniel King Hung Tong; Simon Law; Dora Lai Wan Kwong; Kwok Wah Chan; Alfred King Yin Lam; Kam Ho Wong
Journal:  Ann Surg Oncol       Date:  2010-03-09       Impact factor: 5.344

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.